Boehringer Mannheim Gmbh

Other

Roche Diagnostics Gmbh

Heidelberg Pharma Ag

Dieter Herrmann

Harald Zilch

Elmar Bosies

Alfred Mertens

Hans-George Opitz

Gerd Zimmermann

Herbert Leinert

Wulf Pahlke

Hans-Georg Opitz

Rainer Haag

Johann Hofmann

Hans Hermann Grunicke

Christos Tsaklakidis

Wolfgang Kampe

Uwe Bicker

William E Bauta

Christian Lutz

Christoph Mueller

Michael Schultz

Edgar Voss

Edith Koch

Brigitte Heckl-Oestreicher

Robert Voigt

The subject of the present invention is specific lipidesters of halogenated nucleotides of the following formula wherein R, R, R, X and Y are defined as described herein and salts thereof, said compounds have anti-cancer properties; pharmaceutical compositions containing the compounds, a method of synthesizing the compounds, and a method of using the compounds for treating malignant tumors.

Nucleotide lipid ester derivatives

A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.

Lipid cleavage enzyme

The present invention concerns new phospholipid derivatives of nucleosides of the general formula (I) in which R represents a straight-chained or branched, saturated or unsaturated aliphatic residue with 9-14 carbon atoms which can optionally be substituted once or several times; R can represent a straight-chained or branched, saturated or unsaturated aliphatic residue with 8-12 carbon atoms which can optionally be substituted once or several times; m is 2 or 3; A can represent a methylene group or an oxygen; Nuc can be a nucleoside or a residue derived from a nucleoside derivative; and tautomers thereof and their physiologically tolerated salts of inorganic and organic acids and bases as well as pharmaceutical preparations containing these compounds.

Specific lipid conjugates to nucleoside diphosphates and their use as drugs

The present invention concerns new immunosuppressive and antiviral pharmaceutical agents using lipid alcohols of the general formulae I and II

Lipid alcohols as new immunosuppressive and antiviral drugs

Phospholipid derivatives of phosphono-carboxylic acids, the production

The present invention is directed to new phospholipid derivatives of acyclovir and ganciclovir that link a lipid moiety, which represents a substituted C3 backbone, to acyclovir or ganciclovir via phosphate or thiophosphate. The compounds are particularly suitable for the therapy of viral infections.

Liponucleotides of seco-nucleosides, their production as well as their

The present invention is directed to new nucleoside monophosphate derivatives of lipid ester residues of general formula (I) ##STR1## wherein R.sup.1 represents an optionally substituted alkyl chain having 1-20 carbon atoms;

Lipid esters of nucleoside monophosphates and their use as

Covalent lipid-phosphono-carboxylic acid conjugates and application

The present invention provides a pharmaceutical combination preparation, wherein it contains at least two active materials, the first active material being an inhibitor of protein kinase C and the other active material having an anti-neoplastic action, as well as pharmacologically acceptable carriers and adjuvants.

Method of determining a pharmaceutical combination preparations for use

Compounds of the formula I ##STR1## in which R.sub.1 and R.sub.2 represent a possibly substituted C.sub.8 -C.sub.15 -alkyl chain, n the number 0, 1 or 2 and A the residue of a nucleoside, processes for their preparation, as well as antiviral medicaments which contain these compounds.

Phospholipid derivatives of nucleosides and their use as anti-viral

The present invention provides a method of inhibiting protein kinase C in a mammal having a tumor system which contains protein kinase C, which mammal is undergoing cytostatic therapy. The method comprises administering to the mammal a protein kinase C inhibitor.

Pharmaceutical composition preparation for use in inhibiting protein

Liponucleotides containing an ether linkage in the 2-position and a thioether, sulfoxide, or sulfone linkage in the 3-position. The nucleoside component of said liponucleotide is AZT or 3'-deoxy-3'-fluorothymidine. These compounds exhibit antiviral activity.

Phospholipid derivatives of nucleosides

The present invention provides [3-(C.sub.16 -C.sub.18)-alkaesulphinyl- and -sulphonyl-2-methoxy-methylpropyl]-(2-trimethylammonioethyl) phosphates having superior anti-tumor activity.

[3-(C.sub.16 -C.sub.18)-alkanesulphinyl and

The subject of the present invention is the use of imexon for the production of pharmaceutical compositions with an immunosuppressive action. The present invention also provides pharmaceutical compositions containing imexon and further active materials.

Use of imexon as an immune suppressive and pharmaceutical compositions

The present invention is concerned with the use of compounds of the general formula: ##STR1## and of the pharmacologically acceptable salts thereof, as well as of the optical isomers thereof for the preparation of pharmaceutical compositions with antiviral action. The present invention also provides new phospholipid derivatives.

Growing community of inventors

Heidelberg, Germany

Dieter Herrmann